COVID-19：ロシュの関節炎治療薬トシリズマブ：死亡リスクを軽減（動画）：
RECOVERY Data Shows Roche Tocilizumab Cuts Deaths in COVID-19 Patients:
恢复试验数据表明罗氏关节炎药物可减少住院的COVID-19患者的死亡
治療薬トシリズマブ：
関節炎治療薬トシリズマブが、重度のCOVID-19入院患者の死亡リスクを、軽減します。
- 先週木曜日に発表された結果によると、
- 回復までの時間を短縮し、
- 人工呼吸器の必要性を減らしました。
死亡リスク・軽減効果が判明：
— 2020年3月からCOVID-19のさまざまな治療法を実施、英国・RECOVERY試験から—
多数の混合試験結果の後、トシリズマブがCOVID-19患者に対する死亡リスク・軽減効果が判明しました。
Tocilizumab reduces deaths in patients hospitalised with COVID-19
The RECOVERY trial
has been testing a range of potential treatments for COVID-19 since March 2020.
Tocilizumab, an intravenous drug used to treat rheumatoid arthritis,
was added to the trial in April 2020 for patients with COVID-19 who required oxygen and had evidence of inflammation.
Recruitment to the tocilizumab arm stopped on 24 January 2021 since, in the view of the trial Steering Committee,
sufficient patients had been enrolled to establish whether or not the drug had a meaningful benefit.
A total of 2022 patients were randomly allocated to receive tocilizumab by intravenous infusion and were compared with 2094 patients randomly allocated to usual care alone.
82% of patients were taking a systemic steroid such as dexamethasone.
Treatment with tocilizumab
significantly reduced deaths: 596 (29%) of the patients in the tocilizumab group died within 28 days compared with 694 (33%) patients in the usual care group (rate ratio 0·86; [95% confidence interval [CI] 0·77 to 0·96]; p=0·007),
an absolute difference of 4%.
This means that for every 25 patients treated with tocilizumab, one additional life would be saved.
RECOVERY Trial
https://www.recoverytrial.net/news/tocilizumab-reduces-deaths-in-patients-hospitalised-with-covid-19